Bristol Myers: presents data on advanced melanoma

(CercleFinance.com) - Bristol Myers Squibb presents 10-year historical follow-up data from the CheckMate -067 study that showed a continued and durable long-term survival benefit with Opdivo and Yervoy in the treatment of advanced melanoma.


The data will be presented today as a mini-oral and published simultaneously in The New England Journal of Medicine.

This data represents the longest median overall survival reported from a Phase 3 trial in advanced melanoma.

At ten years, over 40% (43%) of patients treated with Opdivo and Yervoy were alive. Ten years ago, this patient population faced a survival rate of around 25% after just one year.

This data continues to demonstrate the impressive and long-lasting clinical benefits of nivolumab in combination with ipilimumab, with survival curves remaining stable for some years now, said James Larkin, Consultant Medical Oncologist, Department of Medical Oncology, The Royal Marsden.

Remarkably, 43% of patients treated with nivolumab and ipilimumab are alive ten years later, and many have not required further treatment.


Copyright (c) 2024 CercleFinance.com. All rights reserved.